Efficacy Outcomes: Progression-Free Survival, Response Rates, and Duration of Response in MARIPOSA-2

Opinion
Video

This segment focuses on the key efficacy data on progression-free survival, response rates, and duration of response from MARIPOSA-2.

Recent Videos
Stage IV lung cancer may be curable based on the success of the DREAM Program, according to thoracic surgeon, Ankit Bharat, MBBS,
Ankit Bharat, MBBS, a thoracic surgeon, discussed potential treatment emergent adverse effects or complications, as well as strategies for managing them.
Thoracic surgeon, Ankit Bharat, MBBS, discussed surgical strategies among patients with advanced lung cancer diagnoses based on staging.
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Treatment with lorlatinib might be effective regardless of the presence of central nervous system metastases, according to Misako Nagasaka, MD, PhD.
Most central nervous system events with lorlatinib were grade 1 or 2 in the phase 3 CROWN trial.
Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.
Related Content
Significant OS Benefit Observed With NAT Nivolumab/Chemo in Resectable NSCLC

Significant OS Benefit Observed With NAT Nivolumab/Chemo in Resectable NSCLC

Kristi Rosa
June 3rd 2025
Article

Results from CheckMate-816 could be practice-changing after an OS improvement was noted with NAT nivolumab plus chemotherapy in resectable NSCLC.

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

Improving NSCLC Surgery Recovery After Climate Disaster Exposure

Leticia Nogueira, PhD, MPH
March 31st 2025
Podcast

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

An efficacy advantage with osimertinib-containing regimens was consistent across predefined patient subgroups in those with EGFR-mutant NSCLC.

Neoadjuvant Osimertinib Enhances Responses in Resectable EGFR-Mutated NSCLC

Kyle Doherty
June 3rd 2025
Article

An efficacy advantage with osimertinib-containing regimens was consistent across predefined patient subgroups in those with EGFR-mutant NSCLC.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Navigating Management and Dosing Considerations for Amivantamab in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
February 10th 2025
Podcast

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Data from SACHI support savolitinib/osimertinib as a chemotherapy-free option in previously treated EGFR-mutated NSCLC harboring a MET amplification.

Savolitinib Combo Prolongs PFS in Pretreated EGFR+ NSCLC

Kyle Doherty
June 1st 2025
Article

Data from SACHI support savolitinib/osimertinib as a chemotherapy-free option in previously treated EGFR-mutated NSCLC harboring a MET amplification.

HER3-DXd Does Not Yield Improved OS in EGFR-Mutated NSCLC

HER3-DXd Does Not Yield Improved OS in EGFR-Mutated NSCLC

Jason M. Broderick
June 1st 2025
Article

Results from HERTHENA-Lung02 did not show improved OS with HER3-DXd for patients with EGFR-mutated NSCLC.